Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Michael Friedlander, Tarek Meniawy, Ben Markman, Linda R. Mileshkin, Paul R. Harnett, Michael Millward, Joanne Lundy, Alison E. Freimund, Christie Norris, Song Mu, John Wu, Virginia E. Paton, Lai Wang, Bo Gao
Title A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors
Journal Journal of Clinical Oncology
Vol
Issue
Date
URL http://abstracts.asco.org/199/AbstView_199_191325.html
Abstract Text J Clin Oncol 35, 2017 (suppl; abstr 3013)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown uterine cancer not applicable Pamiparib + Tislelizumab Case Reports/Case Series Actionable In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) resulted in a partial response in a patient with uterine cancer (J Clin Oncol 35, 2017 (suppl; abstr 3013)). detail...
Unknown unknown ovarian cancer not applicable Pamiparib + Tislelizumab Case Reports/Case Series Actionable In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in ovarian cancer patients resulted in 1 complete response and 5 partial responses (J Clin Oncol 35, 2017 (suppl; abstr 3013)). detail...
Unknown unknown pancreatic cancer not applicable Pamiparib + Tislelizumab Case Reports/Case Series Actionable In a Phase Ib trial, the combination therapy of of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in patients with pancreatic cancer resulted in one partial response and stable disease for greater than 6 months in two patients (J Clin Oncol 35, 2017 (suppl; abstr 3013)). detail...
Unknown unknown Advanced Solid Tumor not applicable Pamiparib + Tislelizumab Phase Ib/II Actionable In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in patients with advanced solid tumors resulted in 7 patients with a partial response, one patient with a complete response, and 6 patients experiencing stable disease for greater than 6 months (J Clin Oncol 35, 2017 (suppl; abstr 3013)). detail...